| Bioactivity | Colletofragarone A2 can be be isolated from the fungus Colletotrichum sp. (13S020). Colletofragarone A2 inhibits mutant p53 and HSP90 with anti-cancer activity. Colletofragarone A2 promotes degradation and aggregation of mutant p53 and suppressing tumor growth in vivo[1]. |
| Invitro | Mutant p53 loses original tumor suppressor function but acquires new abilities regarding oncogenic progression[1]. Colletofragarone A2 (0.05-5 μM; 72 h) shows high selectivity and more cytotoxic activity on cells with p53R175H structural mutants than with other p53 statuses such as a DNA-contact mutant, wild-type, and null cells[1]. Colletofragarone A2 (2 μM; 8 h) decreases mutant p53 levels in SK-BR-3 (p53R175H) cells by promoting p53 degradation[1].Colletofragarone A2, combinded with 10 μM MG-132 (HY-13259), (2 or 4 μM; 4 h) induces the accumulation of the aggregated mutant p53[1]. Western Blot Analysis[1] Cell Line: |
| In Vivo | Colletofragarone A2 (0.35 mM, 100 μL; injected intratumorally and daily; 13 d) markedly decreases tumor cell growth in mouse infected with HuCCT1 (p53R175H) cells[1]. Animal Model: |
| Name | Colletofragarone A2 |
| Formula | C22H26O6 |
| Molar Mass | 386.44 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sadahiro Y, et al. Colletofragarone A2 Inhibits Cancer Cell Growth In Vivo and Leads to the Degradation and Aggregation of Mutant p53. Chem Res Toxicol. 2022 Aug 26. |